We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Actavis Responds to FDA Request for Comment on Vyvanse Exclusivity
Actavis Responds to FDA Request for Comment on Vyvanse Exclusivity
May 26, 2009
Lawyers representing Actavis Elizabeth have submitted a response to an FDA request for comments to rescind the new chemical entity (NCE) exclusivity for Shire’s attention deficit hyperactivity disorder drug Vyvanse.